Navigation Links
NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Date:10/30/2009

t of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions.
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX to Present at JMP Securities Healthcare Focus Conference
2. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
3. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
4. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
5. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
6. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
7. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Beckman Coulter Announces Conference Call and Webcast of Accompanying Slides in Conjunction With Third Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials Corporation ... sets of patent families from Bayer Technology Services GmbH, ... for Bayer AG of Leverkusen, Germany ... provide broad intellectual property protection for advances ... quantum dot (QD) manufacturing. In addition, the Bayer ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Information Systems ("SIS"), a leader in perioperative ... leadership in achieving clinical, financial, and operational goals ... the company,s annual client conference, the 2012 SIS ... systems exemplifying the innovative use of information technology ...
... 2012 Top leaders representing America,s advanced medical ... public policy issues affecting job creation and medical innovation and ... billion medical device tax set to begin in January 2013. ... Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of ...
Cached Medicine Technology:Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 2Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 3Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 4AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 2AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 3
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 If old ... found a cure for it. With extensive research on HGH ... named ‘MetroMD’ claims to have perfected the art of rubbing ... a brand new younger look with their revolutionary anti-aging hormone ... of the 21st century fountain of youth, the MD of ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... Utah (PRWEB) August 20, 2014 Today, ... new information on open enrollment for 2015. , According ... insurance coming up in November, employees are encouraged to ... seeking coverage in 2015, the open enrollment period will ... During open enrollment 2015 individuals can purchase a new ...
(Date:8/20/2014)... 2014 Attendees of Seedstock’s 3rd Annual ... at Los Angeles’ first multi-faceted food production business incubator ... blossoming 1.5-acre high school campus urban farming operation in ... in the L.A. Art District. , The field trip, ... agriculture, will kick off Seedstock’s “Reintegrating Ag: Local Food ...
(Date:8/20/2014)... MA (PRWEB) August 20, 2014 Verndale ... annual Inc. 500|5000 list; an exclusive list ranking the ... list are ranked according to their yearly percentage revenue ... the 8th time on the Inc. 5000 list where ... Technology Company, Verndale offers its clients a wide range ...
Breaking Medicine News(10 mins):Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... Inc. (Nasdaq: CADX ) announced today that it ... a private placement approximately 12 million shares of the Company,s ... million additional shares of the Company,s common stock, for aggregate ... paid for the common stock, $7.13 per share, is equal ...
... 4:00 PM ET - VALENCIA, Calif., Feb. 17 /PRNewswire-FirstCall/ ... ) today reported financial results for the fourth quarter ... of 2008, total operating expenses were $81.8 million, compared ... Research and development (R&D) expenses increased by $2.0 million ...
... bulk of cases, study finds, , , TUESDAY, Feb. 17 (HealthDay ... loss also have eye disorders, a new study has found. ... ear or to the nerves that link the ear to ... according to background information in the study. Half of all ...
... announced today that it has,received certification of its full ... Standards by the Jefferson School of,Population Health. , ... 10 Quality and Safety Standards in,March of 2007 with ... as its Clinical Advisory Board. A condition of CCA,membership ...
... HotHead Technologies, Inc. today,announced that the technology they ... Kennesaw State University researchers as an early,warning ... "It,s exciting news that research from a university as ... verify much earlier than we anticipated, in,the preliminary stages ...
... Light Press, LLC announces the audio edition of "That,s ... written by co-authors Lil Ingram and Marlene Lee, and ... of HOPE is available in MP3 format at no ... will also be available via the website for the ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Eye Problems, Hearing Loss May Be Linked 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 3Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 4Health News:HotHead Technologies' Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers 2Health News:'That's My Hope' Audio Edition Released 2Health News:'That's My Hope' Audio Edition Released 3
... reads, writes and prints "Smart" labels. As ... or barcode on the label surface. SATO's ... a range of applications, including: Compliance Labeling, ... Tagging, Retail Labeling, Product Authentication. CL408e RFID ...
... is a core software component ... which enables location-based applications in ... capabilities of the AeroScout Engine ... management of AeroScout hardware and ...
... The Kisses tag is part ... of the Hugs system. The Kisses ... mother after it has been bonded ... her baby. he two tags remain ...
... Radianse active-RFID-tags can be ... For example, that a device ... complete or that a patient ... Every message from an ID-tag ...
Medicine Products: